Provention Bio said today that it licensed an enterovirus vaccine platform that it plans to evaluate as a way to prevent the onset of Type I diabetes by vaccinating against infection by a coxsackievirus B pathogen.
Previous work has shown that CVB infection could be responsible for 50% of Type I diabetes cases worldwide, according to the Lebanon, N.J.-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Provention Bio evaluates vaccine to prevent onset of T1D appeared first on MassDevice.